{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:51:26Z","timestamp":1769907086266,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373949"],"award-info":[{"award-number":["82373949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973391"],"award-info":[{"award-number":["81973391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TianQing Hospital Medical Project of the Jiangsu Pharmaceutical Association","award":["T202517"],"award-info":[{"award-number":["T202517"]}]},{"name":"ChangZhouSiYao Hospital Medical Project of the Nanjing Pharmaceutical Association","award":["2024YX002"],"award-info":[{"award-number":["2024YX002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Optimal antimicrobial exposure in epithelial lining fluid (ELF) is critical for meropenem efficacy in pneumonia, yet ELF pharmacokinetic data remain scarce, particularly in children. To address this, we aimed to develop a model capable of predicting meropenem concentrations in both plasma and ELF for evaluating pharmacodynamic target attainment under clinical dosing strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A physiologically based pharmacokinetic (PBPK) model was developed to simulate unbound meropenem concentrations in plasma and ELF. An empirical penetration coefficient (\u03c1) was incorporated to link lung intracellular concentrations to ELF concentrations, modelled as a function of clinical and inflammatory covariates. Following validation, the percentage of time over a dosing interval that the free drug concentration remains above the MIC(%\u0192T &amp;gt; MIC), of meropenem plasma and ELF were related to in-hospital mortality. Monte Carlo simulations were conducted to assess the PTA for 40%\u0192T &amp;gt; \u00a0MIC under varying regimens, MIC ranges (0.25\u201316\u2005mg\/L) and penetration scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PBPK model accurately predicted meropenem exposures in both plasma and ELF. ELF penetration was significantly influenced by physiological and pathological factors. ELF %\u0192T &amp;gt; \u00a0MIC showed higher interindividual variability compared with that of plasma and was more strongly correlated with survival in both adult (P\u200a=\u200a0.073) and paediatric patients (P\u200a=\u200a0.013). Although prolonging the infusion improved ELF target attainment for susceptible pathogens (MIC \u22644\u2005mg\/L) with adequate penetration, it failed against high-MIC strains or with poor lung penetration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings underscore the importance of targeting infection-site pharmacokinetics over plasma exposure for better therapeutic efficacy in pneumonia. The model can be used to optimize dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf500","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:33:08Z","timestamp":1768739588000},"source":"Crossref","is-referenced-by-count":0,"title":["Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK\/PD"],"prefix":"10.1093","volume":"81","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural Medicine, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University , Nanjing ,","place":["China"]},{"name":"Department of Pharmacy, Children's Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa-Sa","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicine, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicine, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Jun","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Children's Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Hua","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Children's Hospital of Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, China Pharmaceutical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Hao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicine, Jiangsu Province Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University , Nanjing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026013007230705000_dkaf500-B1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(20)31550-6","article-title":"Complicated pneumonia in children","volume":"396","author":"de Benedictis","year":"2020","journal-title":"Lancet"},{"key":"2026013007230705000_dkaf500-B2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"2026013007230705000_dkaf500-B3","doi-asserted-by":"publisher","first-page":"e0172923","DOI":"10.1128\/aac.01729-23","article-title":"How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children","volume":"68","author":"Butrague\u00f1o-Laiseca","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/PCC.0b013e318193691a","article-title":"Meropenem use and colonization by antibiotic-resistant gram-negative bacilli in a pediatric intensive care unit","volume":"10","author":"Toltzis","year":"2009","journal-title":"Pediatr Crit Care Med"},{"key":"2026013007230705000_dkaf500-B5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026013007230705000_dkaf500-B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"key":"2026013007230705000_dkaf500-B7","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1128\/AAC.01559-10","article-title":"Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B8","doi-asserted-by":"publisher","first-page":"e01922","DOI":"10.1128\/AAC.01922-18","article-title":"Is one sample enough? \u03b2-lactam target attainment and penetration into epithelial lining fluid based on multiple bronchoalveolar lavage sampling time points in a swine pneumonia model","volume":"63","author":"Motos","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026013007230705000_dkaf500-B10","doi-asserted-by":"publisher","first-page":"2492236","DOI":"10.1080\/19420862.2025.2492236","article-title":"The physiological limits of bispecific monoclonal antibody tissue targeting specificity","volume":"17","author":"Sepp","year":"2025","journal-title":"MAbs"},{"key":"2026013007230705000_dkaf500-B11","doi-asserted-by":"publisher","first-page":"115636","DOI":"10.1016\/j.biopha.2023.115636","article-title":"A physiologically-based pharmacokinetic model for predicting doxorubicin disposition in multiple tissue levels and quantitative toxicity assessment","volume":"168","author":"Chao","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026013007230705000_dkaf500-B12","doi-asserted-by":"publisher","first-page":"107541","DOI":"10.1016\/j.pharmthera.2020.107541","article-title":"Physiologically-based pharmacokinetic models for children: starting to reach maturation?","volume":"211","author":"Verscheijden","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2026013007230705000_dkaf500-B13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-017-1851-6","article-title":"Vasculotide reduces pulmonary hyperpermeability in experimental pneumococcal pneumonia","volume":"21","author":"Gutbier","year":"2017","journal-title":"Crit Care"},{"key":"2026013007230705000_dkaf500-B14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"2026013007230705000_dkaf500-B15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jac\/24.suppl_A.311","article-title":"The pharmacokinetics of meropenem in volunteers","volume":"24","author":"Bax","year":"1989","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"2026013007230705000_dkaf500-B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jac\/36.suppl_A.35","article-title":"A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5\u2005min and intravenous infusion over 30\u2005min","volume":"36","author":"Kelly","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"2026013007230705000_dkaf500-B17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1128\/AAC.36.7.1437","article-title":"Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men","volume":"36","author":"Ljungberg","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1128\/AAC.47.5.1771-1773.2003","article-title":"Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8\u2005hours, in plasma and cantharidin-induced skin blister fluid","volume":"47","author":"Maglio","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40262-021-01046-6","article-title":"Physiologically based pharmacokinetic modeling of meropenem in preterm and term infants","volume":"60","author":"Ganguly","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026013007230705000_dkaf500-B20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.46.2.575-577.2002","article-title":"Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I)","volume":"46","author":"Park","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B21","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1128\/AAC.00497-11","article-title":"Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment","volume":"55","author":"Ikawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B22","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1128\/AAC.36.12.2794","article-title":"Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment","volume":"36","author":"Leroy","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B23","doi-asserted-by":"publisher","first-page":"e0186924","DOI":"10.1128\/aac.01869-24","article-title":"Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis","volume":"69","author":"Al Hroot","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejpb.2020.09.004","article-title":"Pulmonary drug absorption and systemic exposure in human: predictions using physiologically based biopharmaceutics modeling","volume":"156","author":"Eriksson","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"2026013007230705000_dkaf500-B25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/psp4.12252","article-title":"Development of an adult physiologically based pharmacokinetic model of solithromycin in plasma and epithelial lining fluid","volume":"6","author":"Salerno","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026013007230705000_dkaf500-B26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/cpt.1516","article-title":"A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization","volume":"106","author":"Cheung","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026013007230705000_dkaf500-B27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40262-018-00733-1","article-title":"Physiologically based pharmacokinetic modeling for trimethoprim and sulfamethoxazole in children","volume":"58","author":"Thompson","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026013007230705000_dkaf500-B28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0022-3476(86)80245-1","article-title":"A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth","volume":"109","author":"Brion","year":"1986","journal-title":"J Pediatr"},{"key":"2026013007230705000_dkaf500-B29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"2026013007230705000_dkaf500-B30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics and the French Society of Anaesthesia and Intensive Care Medicine","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2026013007230705000_dkaf500-B31","doi-asserted-by":"publisher","first-page":"e00760","DOI":"10.1128\/AAC.00760-20","article-title":"Reappraisal of the optimal dose of meropenem in critically ill infants and children: a developmental pharmacokinetic-pharmacodynamic analysis","volume":"64","author":"Wang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013007230705000_dkaf500-B32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"key":"2026013007230705000_dkaf500-B33","doi-asserted-by":"publisher","first-page":"106868","DOI":"10.1016\/j.ijantimicag.2023.106868","article-title":"Factors associated with meropenem pharmacokinetic\/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion","volume":"62","author":"Tournayre","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026013007230705000_dkaf500-B34","doi-asserted-by":"publisher","first-page":"e0027621","DOI":"10.1128\/jcm.00276-21","article-title":"Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)","volume":"60","author":"Giske","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026013007230705000_dkaf500-B35","author":"DrugBank"},{"key":"2026013007230705000_dkaf500-B36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/psp4.12101","article-title":"Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children","volume":"5","author":"Zhou","year":"2016","journal-title":"CPT Pharmacom Syst Pharmacol"},{"key":"2026013007230705000_dkaf500-B37","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"2026013007230705000_dkaf500-B38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1532-5415.2010.02767.x","article-title":"Competing risk of death: an important consideration in studies of older adults","volume":"58","author":"Berry","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"2026013007230705000_dkaf500-B39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1875041901104010004","article-title":"Pediatric sepsis\u2014part I: \u201cchildren are not small adults!\u201d","volume":"4","author":"Wheeler","year":"2011","journal-title":"Open Inflamm J"},{"key":"2026013007230705000_dkaf500-B40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026013007230705000_dkaf500-B41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/antibiotics11091193","article-title":"Tissue penetration of antimicrobials in intensive care unit patients: a systematic review\u2014part II","volume":"11","author":"Viaggi","year":"2022","journal-title":"Antibiotics"},{"key":"2026013007230705000_dkaf500-B42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijantimicag.2018.11.011","article-title":"Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by gram-negative bacilli: a systematic review","volume":"53","author":"Heffernan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026013007230705000_dkaf500-B43","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/jac\/dky128","article-title":"Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies","volume":"73","author":"Germovsek","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf500\/66640184\/dkaf500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf500\/66640184\/dkaf500.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:23:12Z","timestamp":1769775792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf500\/8445358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf500","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf500"}}